



Centers for Disease Control  
and Prevention (CDC)  
Atlanta GA 30341-3724

Office on Smoking and Health  
U.S. Centers for Disease Control and Prevention  
4770 Buford Highway  
MS F-79  
Atlanta, Georgia 30341-3717

Representative Debra J. Heffernan  
Delaware General Assembly  
411 Legislative Avenue  
Dover, Delaware 19901

Dear Ms. Heffernan,

Per your request, I am submitting this statement of scientific evidence regarding electronic nicotine delivery systems (ENDS; including e-cigarettes), including the health effects of ENDS aerosol. For the record, I am not submitting this statement for or against any specific legislative proposal.

Please note that I will use the term ENDS throughout this letter, except where I am referring to study results that looked at surveillance survey results for a particular product, such as e-cigarettes.

### **Current Status of ENDS Market and Product Regulation**

E-cigarettes are part of a class of products also referred to as electronic nicotine delivery systems (ENDS), which are battery-powered devices that provide doses of nicotine and other additives to the user in an aerosol.<sup>1</sup> There are currently multiple types of ENDS on the U.S. market, including e-cigarettes, e-hookahs, hookah pens, vape pens, e-cigars, and others. Some of these products are disposable varieties, while others can be refilled or recharged for repeated use.

ENDS that do not make therapeutic claims, including e-cigarettes, are currently not regulated by the U.S. Food and Drug Administration (FDA) under the Family Smoking Prevention and Tobacco Control Act (FSPTCA), although FDA issued a proposal in April 2014 to regulate them under its tobacco product authorities.<sup>2</sup> If finalized as written, the rule would establish, among other provisions: restrictions to prevent sales to minors, to prohibit free samples, and to prohibit vending machine sales, unless in a facility that never admits minors.<sup>2</sup> Additional provisions, such as establishing a product standard prohibiting flavors could require additional rule-making.<sup>2</sup>

Furthermore, FDA regulation does not address certain key policy interventions related to ENDS, such as use in public places.<sup>2</sup> Section 916 of the Federal Food, Drug, and Cosmetic Act preserves the authority of States and localities to enact, adopt, promulgate, and enforce laws, rules, regulations or other measures with respect to tobacco products that are in addition to, or more stringent than requirements established under Chapter IX of the Food, Drugs, and Cosmetics Act, including laws, rules, regulations, or other measures relating to or prohibiting the sale, distribution, possession, exposure to, access to, advertising and promotion of, or use of tobacco products by individuals of any age, information reporting to the State, or measures relating to fire safety standards for tobacco products.<sup>3</sup> Section 916, however, prescribes that no State or political subdivision of a State may establish or continue in effect with respect to a tobacco product any requirement which is different from, or in addition to, any requirement under the provisions of Chapter IX of the Federal Food, Drug, and Cosmetic Act relating to

tobacco product standards, premarket review, adulteration, misbranding, labeling, registration, good manufacturing standards, or modified risk tobacco products.<sup>3</sup>

Additional national and—to the extent not preempted by federal law—state policies addressing retailer licensing, Internet sales, taxation, and marketing could further prevent youth use of ENDS and other tobacco products.<sup>4</sup>

The current landscape of ENDS—including product design and availability, sales, marketing, use, and related legislation—is one of rapid change and high variability. Significant questions remain regarding ENDS’ toxicity and impact on patterns of conventional tobacco use. This testimony summarizes the available scientific literature regarding ENDS, including surveillance data on experimentation and recent use; the health effects of ENDS, including toxicant exposure to users and non-users and impacts on patterns of conventional tobacco use; effectiveness of ENDS for quitting conventional smoking; ENDS marketing; smokefree policies and ENDS; and evidence-based strategies to prevent and reduce tobacco use.

### **Current Patterns of ENDS Use**

To date, surveillance questions on the use of ENDS have focused primarily on e-cigarettes. National surveys show rapid increases in adult and youth use of e-cigarettes. Results from the HealthStyles survey suggest that U.S. adult e-cigarette ever use nearly doubled from 2010 (3.3%) to 2013 (8.5%).<sup>5</sup> Data from the National Youth Tobacco Survey show ever use increased in U.S. middle and high school students from 2011 to 2013 (3.3% to 14.9%) and current e-cigarette use (use at least 1 day in the past 30 days) increased from 1.1% to 5.6%.<sup>1,6</sup> More recent survey data from Monitoring the Future suggests an even more dramatic rate of current e-cigarette use among high school students in 2014: 17% among twelfth graders—higher than the use of tobacco cigarettes.<sup>7</sup>

From 2011 to 2013, U.S. middle and high school students who had never smoked cigarettes but who had ever used an e-cigarette increased over three-fold, from approximately 79,000 to over 263,000.<sup>8</sup> Furthermore, intention to smoke conventional cigarettes was 43.9% among U.S. middle and high school students who had ever used e-cigarettes, whereas only 21.5% of students who had never used e-cigarettes reported intending to smoke conventional cigarettes.<sup>8</sup>

These surveillance data also suggest that the majority of adults and youth who use e-cigarettes also use conventional cigarettes.<sup>1,9,10</sup>

### **Health Effects of ENDS**

A discussion of the health effects of ENDS should consider the consequences of toxicant exposure for ENDS to both users and non-users, as well as potential impacts on patterns of use of other tobacco products.

#### **I. Toxicant Exposure to Users**

Since ENDS that do not make therapeutic claims are not yet regulated as tobacco products under the FSPTCA, we have very little information about the ingredients of liquids (purity, impurities or stability), or the approximate exposure to harmful and potentially harmful constituents when using ENDS over the short-term or long-term. To date, manufacturers are not required to publish what chemicals are in the ENDS solution, or to perform or reveal results from systematic testing. Studies have demonstrated wide variability in design, operation, and contents and emissions of carcinogens, other toxicants, and nicotine from ENDS.<sup>11</sup> Depending on the brand, ENDS cartridges typically contain nicotine, a component to produce the aerosol (e.g., propylene glycol or glycerol), and flavorings (e.g., fruit, mint, or chocolate).<sup>12</sup> Chemicals that pose health risks have also been documented in some ENDS, including tobacco-specific nitrosamines, aldehydes, metals, volatile organic compounds, phenolic compounds, polycyclic aromatic hydrocarbons, and tobacco alkaloids, but at much lower levels than in conventional cigarettes.<sup>13</sup> Furthermore, some ENDS manufacturers claim that the use of food flavorings is safe because they

meet the FDA definition of “Generally Recognized as Safe (“GRAS”).<sup>14</sup> However, GRAS status applies to additives for particular food uses, and does not apply to products that are not food.

Although nicotine exposure in the absence of combustion is less hazardous than exposure to combusted conventional tobacco products, nicotine itself is not without risk.<sup>15,16</sup> Nicotine is addictive.<sup>11</sup> Nicotine exposure during certain periods of development can impair the development of brain circuits and neurons, changing the way the brain works.<sup>11,17</sup> Pregnant women can transfer nicotine to their developing fetus, which can be toxic to the fetus, leading to adverse pregnancy and infant outcomes.<sup>11</sup> The evidence is also suggestive that nicotine exposure during adolescence may have lasting adverse consequences for brain development, including cognitive maturation and effects on working memory and attention.<sup>11,18,19,20</sup> For non-smokers, nicotine is an acute irritant, potentially causing headache, nausea, and discomfort; for former smokers, nicotine exposure can trigger cravings, jeopardizing their abstinence.<sup>21,22</sup>

Because of the risks associated with nicotine, the 2014 Surgeon General’s Report concluded that “the evidence is sufficient to provide cautionary messages to pregnant women and women of reproductive age as well as adolescents about the use of nicotine-containing products such as [...] electronic cigarettes, and newer forms of nicotine-containing tobacco products, as alternatives to smoking.”<sup>11</sup>

## **II. Toxicant Exposure to Non-Users**

The health effects of ENDS may not be limited to users.<sup>23,24,25</sup> ENDS aerosol is not “water vapor.” It contains nicotine and can contain additional toxins, and thus, it is not as safe as clean air.<sup>26</sup> Although some ENDS have been shown to emit volatile organic compounds and dangerous toxins such as acetaldehydes, including acrolein, these are generally emitted at much lower levels than by cigarettes.<sup>15</sup> However, because there are hundreds of manufacturers and no manufacturing standards, there is no way to ensure that all ENDS have acceptably low levels of toxicants. Furthermore, some ENDS can be modified to deliver marijuana and other psychoactive substances.<sup>27</sup> Therefore, air containing ENDS aerosol is less safe than clean air, and ENDS use has the potential to involuntarily expose children and adolescents, pregnant women, and non-users to aerosolized nicotine and, if the products are altered, to other psychoactive substances.

All ENDS have the potential to involuntarily expose children and adolescents, pregnant women, and non-users to aerosolized nicotine. In addition, FDA does not regulate the use of ENDS use, particularly in public places, and the issue of involuntary exposure among bystanders to ENDS aerosol.

## **III. Additional Hazards**

ENDS use can result in accidents and other potential health hazards. CDC recently reported that the number of calls to poison centers in the 50 states, the District of Columbia, and U.S. territories involving e-cigarettes rose from one per month in September 2010 to 215 per month in February 2014, and 51.1% of these e-cigarette-related poisonings were among young children ages 0–5.<sup>28</sup> In the U.S., e-cigarettes account for a small proportion of total tobacco product sales, but were involved in nearly 42% of combined monthly cigarette and e-cigarette poison center calls in February 2014.<sup>29</sup> Health-care providers; the public health community; e-cigarette manufacturers, distributors, sellers, and marketers; and the public should be aware that e-cigarettes have the potential to cause acute adverse health effects and represent an emerging public health concern.

An increasingly popular method of ENDS use is to self-mix the e-liquid—both the nicotine content and the flavorings—prior to use. In this way, individuals can produce a customized ENDS product. There are also reports in the news media about the potential for e-cigarettes to be altered to deliver other psychoactive substances such as THC, the active ingredient in marijuana.<sup>29,30</sup> Importantly, the health risks of secondhand exposure to such self-mixed concoctions are unknown.

## **IV. Impact of ENDS on Patterns of Tobacco Use**

There are a range of potential beneficial and harmful impacts of ENDS on patterns of use of cigarettes and other combusted tobacco products. The Surgeon General has stated that cigarettes and other combusted tobacco products are the “overwhelming cause [of] the burden of death and disease from tobacco use in the United States” and recommends that “rapid elimination of their use will dramatically reduce this burden.”<sup>11</sup> The 2014 Surgeon General’s Report notes that ENDS—in combination with rigorous surveillance and aggressive strategies to end combusted tobacco use—could help complement strategies to eliminate combusted tobacco use by allowing complete nicotine substitution among cigarette smokers.<sup>11</sup>

In the current context, cigarettes and other combusted tobacco products are widely available, heavily marketed, inexpensive, and appealing to young people.<sup>11</sup> In this context of widespread marketing and availability of cigarettes and other combustible tobacco products, there are a number of potential adverse consequences of ENDS on tobacco use patterns.<sup>11</sup> Among youth, risks include: (1) aforementioned concerns about nicotine addiction and consequences of nicotine on brain development, (2) initiation of the use of cigarettes or other combusted tobacco products as a result of introduction to inhalation of nicotine delivered via ENDS, (3) exposure to ENDS marketing and use that normalizes a behavior that looks very similar to smoking, and (4) use of combusted and noncombustible tobacco products at the same time (“dual use”).<sup>9,13,31</sup> The potential for ENDS to renormalize tobacco use is of concern, because adolescents are particularly vulnerable to visual cues to smoke and to social norms.<sup>4,31</sup> Again, a recent study found that among never-smoking youth who had ever used an e-cigarette, their intention to smoke conventional cigarettes was 22.4% higher than among youth who had never used e-cigarettes (43.9% v. 21.5%, respectively).<sup>8</sup> To advance the public health goal of preventing youth initiation of tobacco use, youth should not be able to purchase or be exposed to marketing for any tobacco products, including ENDS.<sup>4,31</sup>

Among adults, potential adverse consequences include: (1) initiation of nicotine addiction among non-tobacco users and potential for progression to combusted tobacco use; (2) long-term dual use among current smokers, which may result in delayed quitting; and (3) relapse of smoking among former smokers.<sup>11</sup>

As noted above, current evidence shows that the majority of adults and youth who are using e-cigarettes are also using conventional cigarettes; among current e-cigarette users, the proportion of current cigarette smokers was 72% during 2010/2011 and 76.8% during 2012/2013.<sup>1,5</sup> This is of concern because only cutting down on the number of cigarettes smoked does not significantly reduce tobacco-related health risks.<sup>32,33</sup>

### **Evidence of Effectiveness for Quitting Smoking**

To date, no ENDS, including e-cigarettes, have been approved as a smoking cessation aid by the Food and Drug Administration’s Center for Drug Evaluation and Research, and there is limited research on their effectiveness as a cessation aid.<sup>22</sup> There is currently no conclusive scientific evidence that ENDS promote long-term cessation, especially at the population level.<sup>34,35,36,37,38,39,40</sup> Currently, seven types of FDA-approved prescription and non-prescription smoking cessation products are available, including nicotine replacement therapies. These products have been scientifically shown to be effective for smoking cessation, approved by the FDA for this use, and are safe when used as directed. ENDS marketed as smoking cessation aids must be approved for such use by the FDA Center for Drug Evaluation and Research.

### **ENDS Marketing**

Although conventional tobacco products have been banned from television advertising for decades, ENDS are now marketed on television and other mainstream media channels. Like the products themselves, marketing claims for ENDS vary widely. The 2014 Surgeon General’s Report observed that ENDS marketing “has included claims of safety, use for smoking cessation, and statements that they are exempt from clean air policies that restrict smoking.”<sup>11</sup> Moreover, some ENDS marketing uses tactics which the Surgeon General has found lead to youth smoking, including: candy-flavored products; youth-resonant themes such as rebellion, glamour, and sex; and celebrity endorsements and sports and music sponsorships.<sup>31</sup> This is of concern because the Surgeon General has found that “many changes in tobacco product form and marketing have been documented as efforts by the

tobacco industry to contribute to tobacco use and addiction by fostering initiation among young people; making products easier and more acceptable to use; making and marketing products so as to address health concerns; and making and marketing products to perpetuate addiction through the use of alternate products, when smoking is not allowed or is socially unacceptable.”<sup>11</sup>

### **Smokefree Policies and ENDS**

As mentioned earlier, air containing ENDS aerosol is less safe than clean air, and ENDS use has the potential to involuntarily expose children and adolescents, pregnant women, and non-users to aerosolized nicotine and, if the products are altered, to other psychoactive substances.<sup>41</sup> Therefore, clean air—free of both smoke and ENDS aerosol—remains the standard to protect health.

The majority of e-cigarette users also smoke cigarettes.<sup>1,10</sup> Permitting ENDS use in public places could perpetuate combusted tobacco use and, therefore, tobacco-related morbidity and mortality. For example, ENDS use in public places could make it easier for smokers to sustain their nicotine addiction in public places, without switching completely away from combusted tobacco use. There is no evidence to support any claim that policies that allow ENDS use in public places result in smokers switching to ENDS completely. Additionally, because some e-cigarettes are designed to mimic smoking, allowing ENDS use in places where smoking is prohibited could complicate enforcement of smokefree policies and renormalize tobacco use.<sup>42</sup>

### **Conclusion**

ENDS have a range of potential impacts on individual and population health, and significant questions remain regarding their toxicity and impact on patterns of conventional tobacco use. In contrast, considerable and conclusive evidence exists on the health harms of cigarettes and other combusted tobacco products among both users and non-users. Moreover, the scientific literature supports the safety and effectiveness of FDA-approved cessation aids when used as directed.

Given what we know about the harms of cigarettes and other combusted tobacco products, we should not lose sight of the importance of tobacco prevention and control. However, given what we also know about nicotine addiction, the harms of nicotine exposure—especially to the adolescent brain—and the fact that ENDS that do not make therapeutic claims are not currently regulated, the scientific evidence supports a public health approach to first “do no harm.” Ensuring children and youth do not have access to ENDS, preventing ENDS use among children and youth, reducing the appeal of ENDS to children and youth, protecting nonusers from involuntary exposure to ENDS aerosol, and ensuring smokers who want to quit have access to proven cessation methods are all ways we can promote public health and protect vulnerable populations from potential harms.

Thank you for your attention to this important public health issue.

Thank you for your inquiry.

Sincerely,

A handwritten signature in black ink, appearing to read 'Tim McAfee', written over a light blue rectangular background.

Tim McAfee, MD, MPH  
Senior Medical Officer  
Office on Smoking and Health  
Centers for Disease Control and Prevention  
U.S. Department of Health and Human Services

- 
- <sup>1</sup> Centers for Disease Control and Prevention. Notes from the field: electronic cigarette use among middle and high school students—United States, 2011–2012. *Morbidity and Mortality Weekly Report* 2013, 62(35):729-730.
- <sup>2</sup> Food and Drug Administration. “Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products; Proposed Rule.” 79 Federal Register 80 (25 April 2014), pp. 23142–23207.
- <sup>3</sup> Pub. L. 111–31 (2009).
- <sup>4</sup> Marynak K, Holmes CB, King BA, Promoff G, Bunnell R, McAfee T. State laws prohibiting sales to minors and indoor use of electronic nicotine delivery systems—United States, November 2014. *Morbidity and Mortality Weekly Report* 2014, 63(49):1145–50.
- <sup>5</sup> King BA, Patel R, Nguyen KH, Dube SR. Trends in awareness and use of electronic cigarettes among U.S. adults, 2010–2013. *Nicotine and Tobacco Research*. First published online September 19, 2014: doi:10.1093/ntr/ntu191.
- <sup>6</sup> Arrazola RA, Neff LJ, Kennedy SM, Holder-Hayes E, Jones CD. Tobacco use among middle and high school students—United States, 2013. *Morbidity and Mortality Weekly Report* 2014, 63(45):1021–6.
- <sup>7</sup> University of Michigan. “E-cigarettes surpass tobacco cigarettes among teens.” Available from: <http://monitoringthefuture.org/pressreleases/14cigpr.pdf>. Accessed March 9, 2015.
- <sup>8</sup> Bunnell RE, Agaku IT, Arrazola RA, Apelberg BJ, Caraballo RS, Corey CG, Coleman BN, Dube SR, King BA. Intentions to smoke cigarettes among never-smoking U.S. middle and high school electronic cigarette users, National Youth Tobacco Survey, 2011–2013. *Nicotine and Tobacco Research* 2014. doi: 10.1093/ntr/ntu166.
- <sup>9</sup> King BA, Alam S, Promoff G, Arrazola R, Dube SR. Awareness and ever-use of electronic cigarettes among U.S. adults, 2010–2011. *Nicotine and Tobacco Research* 2013, 15(9):1623–1627.
- <sup>10</sup> King BA, Patel R, Nguyen KH, Dube SR. Trends in awareness and use of electronic cigarettes among U.S. adults, 2010–2013. *Nicotine and Tobacco Research*. First published online September 19, 2014: doi:10.1093/ntr/ntu191.
- <sup>11</sup> U.S. Department of Health and Human Services. *The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General*. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
- <sup>12</sup> Cobb N K, Byron MJ, Abrams DB, Shields PG. Novel nicotine delivery systems and public health: the rise of the "e-cigarette". *American Journal of Public Health* 2010, 100(12): 2340–2.
- <sup>13</sup> Cheng T. Chemical evaluation of electronic cigarettes. *Nicotine and Tobacco Research* 2014, 23: ii11–17. doi: 10.1136/tobaccocontrol-2013-051482.
- <sup>14</sup> E-cig. Banana Flavor 30 mL E-Juice E-Liquid. Available from: <http://www.e-cig.com/banana-flavor-30ml-e-juice-e-liquid>, Accessed March 11, 2015.
- <sup>15</sup> Goniewicz, ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-Czapla M, Rosik-Dulewska C, Havel C, Jacob P, Benowitz N. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. *Tobacco Control* 2014,23(2): 133–9.
- <sup>16</sup> U.S. Department of Health and Human Services. *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General*. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2010.
- <sup>17</sup> Thompson BL, Levitt P, Stanwood GD. Prenatal exposure to drugs: effects on brain development and implications for policy and education. *Nature Reviews: Neuroscience* 2009: 10(4):303–12. <http://dx.doi.org/10.1038/nm2598>.
- <sup>18</sup> Poorthuis RB, Goriounova NA, Couey JJ, Mansvelder HD. Nicotinic actions on neuronal networks for cognition: general principles and long-term consequences. *Biochem Pharmacol* 2009;78(7):668–676. <http://dx.doi.org/10.1016/j.bcp.2009.04.031>.

- 
- <sup>19</sup> Jacobsen LK, Krystal JH, Menci WE, Westerveld M, Frost SJ, Pugh KR. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. *Biol Psychiatry* 2005;57:56–66. <http://dx.doi.org/10.1016/j.biopsych.2004.10.022>.
- <sup>20</sup> Musso F, Bettermann F, Vucurevic G, Stoeter P, Konrad A, Winterer G. Smoking impacts on prefrontal attentional network function in young adult brains. *Psychopharmacology (Berl)*. 2007;191:159–169. <http://dx.doi.org/10.1007/s00213-006-0499-8>.
- <sup>21</sup> Benowitz, N. L. (1986). "Clinical pharmacology of nicotine." *Annu Rev Med* 37: 21-32.
- <sup>22</sup> 2008 PHS Guideline Update Panel (2008). Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. *Respir Care* 53(9): 1217-1222.
- <sup>23</sup> Schripp, T., D. Markewitz, E. Uhde and T. Salthammer (2013). "Does e-cigarette consumption cause passive vaping?" *Indoor Air* 23(1): 25-31.
- <sup>24</sup> Williams, M., A. Villarreal, K. Bozhilov, S. Lin and P. Talbot (2013). "Metal and silicate particles including nanoparticles are present in electronic cigarette cartomizer fluid and aerosol." *PLoS One* 8(3): e57987.
- <sup>25</sup> Zhang, Y., W. Sumner and D. R. Chen (2013). "In vitro particle size distributions in electronic and conventional cigarette aerosols suggest comparable deposition patterns." *Nicotine Tob Res* 15(2): 501-508.
- <sup>26</sup> Goniewicz, M. L., T. Kuma, M. Gawron, J. Knysak and L. Kosmider (2013). "Nicotine levels in electronic cigarettes." *Nicotine Tob Res* 15(1): 158-166.
- <sup>27</sup> Durmowicz E.L. The impact of electronic cigarettes on the paediatric population. *Tob Control* 2014; 23:ii41–6.
- <sup>28</sup> CDC (2014). "Notes from the Field: Calls to Poison Centers for Exposures to Electronic Cigarettes — United States, September 2010–February 2014." *MMWR Morb Mortal Wkly Rep* 63(13): 292–293.
- <sup>29</sup> CBS Los Angeles (2014). "More Young Students Using Electronic Cigarettes, Marijuana Oil to get High During Class." January 14, 2014. Available at: <http://losangeles.cbslocal.com/2014/01/14/more-young-students-using-electronic-cigarettes-marijuana-oil-to-get-high-during-class/>.
- <sup>30</sup> Welch, William M. (2014). "Vaporizers, e-cigs of the pot world, are booming." *USA Today*. March 17, 2014. Available at: <http://www.usatoday.com/story/money/business/2014/03/15/marijuana-vaporizing-gains/6042675/>
- <sup>31</sup> U.S. Department of Health and Human Services (2012). Reports of the Surgeon General. *Preventing Tobacco Use Among Youth and Young Adults: A Report of the Surgeon General*. Atlanta (GA), Centers for Disease Control and Prevention (US).
- <sup>32</sup> Godtfredsen, N. S., C. Holst, E. Prescott, J. Vestbo and M. Osler (2002). "Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies." *Am J Epidemiol* 156(11): 994-1001.
- <sup>33</sup> Tverdal, A. and K. Bjartveit (2006). "Health consequences of reduced daily cigarette consumption." *Tob Control* 15(6): 472-480.
- <sup>34</sup> Adkison S.E., O'Connor R.J., Bansal-Travers M., Hyland A., Borland R., Yong H.H., Cummings K.M., McNeill A., Thrasher J.F., Hammond D., Fong G.T. "Electronic nicotine delivery systems: international tobacco control four-country survey." *Am J Prev Med* 2013 Mar;44(3):207–15.
- <sup>35</sup> Brown J., Beard E., Kotz D., Michie S., West R. "Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study." *Addiction* 2014 Sep;109(9):1531–40.
- <sup>36</sup> Etter J.F., Bullen C. "A longitudinal study of electronic cigarette users." *Addict Behav* 2014 Feb;39(2):491–4.
- <sup>37</sup> Grana, R. A., L. Popova and P. M. Ling (2014). "A Longitudinal Analysis of Electronic Cigarette Use and Smoking Cessation." *JAMA Intern Med*.
- <sup>38</sup> Polosa R., Caponnetto P., Morjaria J.B., Papale G., Campagna D., Russo C. "Effect of an electronic nicotine delivery device (e-cigarette) on smoking reduction and cessation: a prospective 6-month pilot study." *BMC Public Health* 2011 Oct 11; 11:786. doi: 10.1186/1471-2458-11-786.
- <sup>39</sup> Siegel M.B., Tanwar K.L., Wood K.S. "Electronic cigarettes as a smoking-cessation tool: results from an online survey." *Am J Prev Med* 2011 Apr;40(4):472–5.
- <sup>40</sup> Vickerman K.A., Carpenter K.M., Altman T., Nash C.M., Zbikowski S.M. "Use of electronic cigarettes among state tobacco cessation quitline callers." *Nicotine Tob Res* 2013 Oct;15(10):1787–91.

---

<sup>41</sup> Ballbé M, Martínez-Sánchez JM, Sureda X, et al. Cigarettes vs. e-cigarettes: passive exposure at home measured by means of airborne marker and biomarkers. *Environmental Res* 2014;135C:76–80. Epub ahead of print.

<sup>42</sup> Babej ME (2013). NJOY: The e-cigarette that aims to snuff out smoking. *Forbes*. July 18, 2013. Available at: <http://www.forbes.com/sites/marcbabej/2013/07/18/njoy-the-e-cigarette-that-aims-to-snuff-out-smoking/>